FDA Breakthrough status for Immunomedics breast cancer candidate

FDA Breakthrough status for Immunomedics breast cancer candidate

The company's sacituzumab govitecan, or IMMU-132, has received this designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who have failed at least 2 prior therapies for metastatic disease. The Breakthrough …

(Visited 3 times, 1 visits today)
4
Like
Save

Comments

Comments are disabled for this post.